Acadia Pharmaceuticals (NASDAQ:ACAD)’s share price reached a new 52-week high and low on Friday . The company traded as low as $21.81 and last traded at $22.47, with a volume of 3837800 shares traded. The stock had previously closed at $23.11.
A number of research firms have recently weighed in on ACAD. BidaskClub raised shares of Acadia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, February 17th. Zacks Investment Research cut shares of Acadia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. Finally, ValuEngine cut shares of Acadia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, March 23rd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $49.50.
The company has a market cap of $2,802.05, a P/E ratio of -9.52 and a beta of 3.53.
In other Acadia Pharmaceuticals news, Director Daniel B. Soland acquired 7,000 shares of the stock in a transaction that occurred on Thursday, March 1st. The shares were purchased at an average cost of $23.91 per share, with a total value of $167,370.00. Following the purchase, the director now owns 2,000 shares in the company, valued at $47,820. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Glenn Baity sold 36,558 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $32.39, for a total transaction of $1,184,113.62. Following the completion of the sale, the executive vice president now directly owns 83,734 shares in the company, valued at $2,712,144.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 135,879 shares of company stock worth $4,175,649. 22.25% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in Acadia Pharmaceuticals by 5.0% in the 4th quarter. BlackRock Inc. now owns 6,710,697 shares of the biopharmaceutical company’s stock valued at $202,060,000 after acquiring an additional 321,950 shares during the last quarter. Janus Henderson Group PLC grew its stake in Acadia Pharmaceuticals by 62.7% in the 3rd quarter. Janus Henderson Group PLC now owns 5,958,548 shares of the biopharmaceutical company’s stock valued at $224,459,000 after acquiring an additional 2,295,881 shares during the last quarter. Franklin Resources Inc. grew its stake in Acadia Pharmaceuticals by 5.5% in the 4th quarter. Franklin Resources Inc. now owns 3,237,846 shares of the biopharmaceutical company’s stock valued at $97,492,000 after acquiring an additional 169,057 shares during the last quarter. Fred Alger Management Inc. lifted its holdings in Acadia Pharmaceuticals by 8.3% in the 4th quarter. Fred Alger Management Inc. now owns 2,166,029 shares of the biopharmaceutical company’s stock valued at $65,219,000 after purchasing an additional 165,595 shares in the last quarter. Finally, First Trust Advisors LP lifted its holdings in Acadia Pharmaceuticals by 25.8% in the 4th quarter. First Trust Advisors LP now owns 1,523,112 shares of the biopharmaceutical company’s stock valued at $45,861,000 after purchasing an additional 312,671 shares in the last quarter. 96.24% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Acadia Pharmaceuticals (ACAD) Reaches New 52-Week High and Low at $21.81” was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2018/04/01/acadia-pharmaceuticals-acad-reaches-new-52-week-high-and-low-at-21-81.html.
Acadia Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Receive News & Ratings for Acadia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.